Key facts
- It has raised $40.3M; the latest was Early Stage VC ($40.3M) in Feb 2026.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Yuzun International
- ·The full record, as it builds
Funding rounds
No funding rounds for Yuzun International are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Yuzun International
Provider of advanced biotechnological research and experimental development services intended to accelerate innovation in biomedicine, gene editing, and cell therapy. The company offers international clinical trial collaboration, biosafety laboratories, and integrated research-to-application platforms, enabling pharmaceutical enterprises and healthcare institutions to advance drug development and therapeutic breakthroughs.
- Sector
- Healthcare
- HQ
- Haikou, China
- Founded
- 2023
- Employees
- 45
- Ownership
- Privately Held (backing)
Yuzun International doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Yuzun International shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Yuzun International in its N-PORT filings yet. We sweep new filings monthly.